Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

294.11
-4.2000-1.41%
Post-market: 299.995.88+2.00%17:13 EDT
Volume:644.20K
Turnover:192.74M
Market Cap:8.19B
PE:-21.83
High:312.29
Open:298.40
Low:293.57
Close:298.31
52wk High:356.00
52wk Low:26.70
Shares:27.85M
Float Shares:25.78M
Volume Ratio:1.41
T/O Rate:2.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.4758
EPS(LYR):-13.4758
ROE:-45.83%
ROA:-28.69%
PB:9.33
PE(LYR):-21.83

Loading ...

BUZZ-Praxis Precision Medicines edges down after $575 mln stock sale

Reuters
·
Jan 07

Praxis Precision Medicines Prices $575 Million Common Stock Offering

MT Newswires Live
·
Jan 07

Praxis Precision Medicines Inc - Prices Public Offering of 2,212,000 Shares at $260 per Share

THOMSON REUTERS
·
Jan 07

Press Release: Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Dow Jones
·
Jan 07

Praxis Precision Medicines Plans Public Offering of Common Shares, Warrants

MT Newswires Live
·
Jan 07

BRIEF-Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Reuters
·
Jan 07

Praxis Precision Heading for 'Exciting' 2026, Truist Says

MT Newswires Live
·
Dec 30, 2025

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug

Benzinga_recent_news
·
Dec 30, 2025

Praxis Shares Rise on Ulixacaltamide Breakthrough Designation

Dow Jones
·
Dec 29, 2025

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Benzinga
·
Dec 29, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Vail Resorts, Tonix, Praxis Precision, AXT

Reuters
·
Dec 29, 2025

Sector Update: Health Care

MT Newswires Live
·
Dec 29, 2025

BUZZ-Praxis Precision climbs after FDA's 'breakthrough' tag for tremor drug

Reuters
·
Dec 29, 2025

FDA Grants Breakthrough Therapy Designation to Praxis Precision Medicines' Ulixacaltamide for Essential Tremor

Reuters
·
Dec 29, 2025

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide Hcl in Essential Tremor

THOMSON REUTERS
·
Dec 29, 2025

Praxis Precision Medicines Inc - to Submit Ulixacaltamide Nda in Early 2026

THOMSON REUTERS
·
Dec 29, 2025

U.S. RESEARCH ROUNDUP-Expedia Group, Hasbro, Palisade Bio

Reuters
·
Dec 29, 2025

Praxis Precision Medicines Inc : Btig Raises Target Price to $843 From $507

THOMSON REUTERS
·
Dec 29, 2025

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Dec 29, 2025

FDA-Endorsed Elsunersen Trial Redesign Could Be A Game Changer For Praxis Precision Medicines (PRAX)

Simply Wall St.
·
Dec 23, 2025